logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Burosumab for tumour-induced osteomalacia

< Back

Burosumab for tumour-induced osteomalacia

Drugs

Cancer and Palliative Care

January 2021


Burosumab is in clinical development for the treatment of adults with tumour-induced osteomalacia (TIO). TIO is a rare disease where an overproduction of FGF23 leads to renal phosphate wasting and low levels of phosphate and vitamin D in the body. This causes weakening (or softening) of bones. Main symptoms include bone pain, muscle weakness/fatigue and fractures and without a timely diagnosis, TIO can lead to a significant decrease in quality of life, severe functional impairment and even prostration.
Burosumab is administered by subcutaneous injection. Burosumab is designed to recognise and attach to a protein called FGF23. By attaching to the FGF23 protein, burosumab blocks its activity, thus restoring phosphate and vitamin D levels by achieving phosphate homeostasis. If licensed, burosumab will provide a treatment option for TIO.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts